Annual Review 2011

Many of the drug classes which are included in the prior authorization program are reviewed each fiscal year.  These reports include detailed statistics on utilization, prior authorization, market share, new products, and other notable events for the category during the previous year.  These reports were not included on a DUR Board agenda and are in addition to the utilization reports included with the DUR Board packets.

FY 2011

Albuterol Inhalers
Amitiza
Antiemetics
Anti-migraine
Anxiolytics
Bladder Control
Brovana
Byetta_Victoza
Elidel_Protopic
Fibric Acid Derivatives
Fibromyalgia
Glaucoma
Glumetza and Fortamet
Insomnia
Lamisil
Muscle Relaxants
Ocular Allergy
Osteoporosis
Otic Antibiotics
Plavix and Effient
PPIs
Qualaquin
Smoking Cessation
Stimulants
Symlin
Topical Antifungals
Xolair
Xopenex